Galectin Therapeutics Inc. (GALT)

[biotech2010]

You are taking my comments way out of contexr.

I think they made a mistake in pre-announcing the release of the Cohort 2 data but never would consider that they intentionally misled shareholders. You are jumping all over the difference in sampling as a mistake that was a management 'plot' when it was just a change in sampling.

I asked Dr Traber why the change and why they didn't also do the 14 day results during the conference call and it would have delayed the Cohort 2 because the FDA would have had to approve this ahead of time.

Dr Traber was the CMO of Glaxo Smith Kline, he knows how to bring new drugs through trials and is an asset to GALT, not an anchor; without him the company would be long gone and extinct due to the gross mismanagement of Platt.

I won't comment on this again, there is nothing more than I can add.